Journal
CANCERS
Volume 13, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cancers13071641
Keywords
colon cancer; metabolism; metastasis
Categories
Funding
- Agencia de Gestio d'Ajuts Universitaris I de Recerca from the Catalan Government [2017SGR1033]
- MCIU/AEI/FEDER, UE [SAF2017-89673-R]
- MINECO/FEDER, UE [SAF2015-70270-REDT]
- Instituto de Salud Carlos III (CIBEREHD) [CB17/04/00023]
- ICREA Academia
Ask authors/readers for more resources
The search for new therapeutic opportunities to target cancer metastasis is crucial for the improvement of cancer treatment. Metabolic adaptation is an important hallmark of cancer and metastasis, and targeting metabolic pathways represents a promising strategy to specifically target metastatic cells, especially in colorectal cancer metastasis. Expanding research in this field may lead to the development of new therapeutic strategies for metastatic colorectal cancer.
Simple Summary The search for new therapeutic opportunities to target cancer metastasis is crucial for the improvement of cancer treatment. One of the characteristics of tumoral and metastatic cells is the capacity to reorganize their metabolism, together with the ability to grow faster, migrate and form new tumours in distant sites. Therefore, the pharmaceutical inhibition of metabolic pathways represents a promising strategy to specifically target metastatic cells, especially in colorectal cancer metastasis. Metabolic adaptation is emerging as an important hallmark of cancer and metastasis. In the last decade, increasing evidence has shown the importance of metabolic alterations underlying the metastatic process, especially in breast cancer metastasis but also in colorectal cancer metastasis. Being the main cause of cancer-related deaths, it is of great importance to developing new therapeutic strategies that specifically target metastatic cells. In this regard, targeting metabolic pathways of metastatic cells is one of the more promising windows for new therapies of metastatic colorectal cancer, where still there are no approved inhibitors against metabolic targets. In this study, we review the recent advances in the field of metabolic adaptation of cancer metastasis, focusing our attention on colorectal cancer. In addition, we also review the current status of metabolic inhibitors for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available